Detalles de la búsqueda
1.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Ann Oncol
; 32(8): 1015-1024, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34102253
2.
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Ann Oncol
; 32(10): 1307, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412950
Resultados
1 -
2
de 2
1
Próxima >
>>